Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Research And Development Expense by Product
Other Costs$7.07M+88.7%$6.68M+137%$5.63M+130%$4.75M+135%$3.75M+109%
Preclinical Programs External Expenses$17.61M+11.1%$16.57M+0.2%$15.68M+5.3%$14.92M+17.0%$15.85M+82.5%
RAP219Program External Expenses$49M+87.4%$41.14M+86.3%$34.13M+102%$30.98M+124%$26.14M+126%
Research And Development Personnel Related Costs Including Stock-Based Compensation$34.26M+53.8%$30.4M+55.9%$26.3M+59.2%$24.35M+79.3%$22.27M+94.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How does Rapport Therapeutics, Inc. break its business down?
Rapport Therapeutics, Inc. (RAPP) reports selling general and administrative expense by product across 3 parts — Facility Related And Other, General And Administrative Personnel Related Costs Including Stock-Based Compensation and Professional And Consulting Costs. Each is extracted from the segment footnotes and tracked over time.
Where does Rapport Therapeutics, Inc.'s segment data come from?
Segment breakdowns are pulled from the segment footnotes in Rapport Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.